Pfizer says its vision is to live in “a world where people with cancer live better and longer lives.” To show its dedication to cancer research, 40% of its funds for research and development go to improving cancer therapy. In 2023, Pfizer’s medicine to help treat prostate cancer was approved, as was an antibody that assists the immune system in people with blood cancer multiple myeloma. A clinical trial found a promising treatment for bladder cancer and with Pfizer’s acquisition of cancer treatment company Seagen, the company seems likely to increase its clinical trials twofold.

Additionally, Pfizer has partnered with the American Cancer Society to raise awareness of early screenings for underrepresented communities. This multi-year partnership will open up more clinical trials for these communities while supporting their health outcomes. Pfizer also offers resources for cancer patients and caregivers, offering ways to stay active, improve mental health, share personal stories, and connect with financial support for treatment.